Ildong Holdings (000230) Fundamentals 2026 — P/E 2.8x, Revenue Analysis | SniperIQ
Ildong Holdings (000230) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩70.2B, trading at ₩6080.00 on the KSC. This SniperIQ fundamentals page covers Ildong Holdings's valuation (P/E 2.8x, P/B 1.7x), profitability (net margin 2.7%), revenue (₩590.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ildong Holdings's market cap?
Ildong Holdings (000230) has a market capitalization of approximately ₩70.2B, trading at ₩6080.00 on the KSC. Market cap moves with the live share price.
What is Ildong Holdings's P/E ratio?
Ildong Holdings's trailing twelve-month P/E ratio is 2.8x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ildong Holdings?
Ildong Holdings runs a net profit margin of 2.7%, a gross margin of 38.0%, and an operating margin of 3.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ildong Holdings generate?
Ildong Holdings reported revenue of ₩590.9B for fiscal year 2025, with net income of ₩10.9B and earnings per share (EPS) of 966.78. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ildong Holdings pay a dividend?
Ildong Holdings offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ildong Holdings financially healthy?
Ildong Holdings carries a debt-to-equity ratio of 1.10x and a current ratio of 0.80x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ildong Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ildong Holdings (000230) the key facts are: market cap ₩70.2B, P/E 2.8x, revenue ₩590.9B, 52-week range 5660-17170. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ildong Holdings's full fundamentals live
Get Ildong Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.